Loading
A phase 2 trial of MCLA-129 in lung cancer, run by Betta Pharmaceuticals Co., Ltd., not yet recruiting.
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. is a phase 2, interventional study registered as NCT06885840 by Betta Pharmaceuticals Co., Ltd., with a registry enrolment figure of 100 participants, started 2025-03-31 and due to reach its primary completion in 2028-04. Interventions recorded: MCLA-129. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Overall Response Rate (ORR). Lung eligibility wording from the registry: "* Subjects must have histologically or cytologically confirmed locally advanced unresectable or metastatic NSCLC". Sites: China. No results are recorded here; the registry entry is the source.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Betta Pharmaceuticals, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.